Evidence map›Paper›PMID 22005303›Full record

ArticleThe Journal of clinical investigation2011

Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.

Wanli Ma, Weihong Han, Peter A Greer, Rubin M Tuder, Haroldo A Toque, Kevin K W Wang, R William Caldwell, Yunchao Su

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 115 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Signaling pathways and targeted therapy for pulmonary hypertension.Signal transduction and targeted therapy · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Calpain Promotes LPS-induced Lung Endothelial Barrier Dysfunction via Cleavage of Talin.American journal of respiratory cell and molecular biology · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.International journal of molecular sciences · 2022
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Wanli MaDepartment of Pharmacology and Toxicology, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, USA.
Weihong Han
Peter A Greer
Rubin M Tuder
Haroldo A Toque
Kevin K W Wang
R William Caldwell
Yunchao Su
Augusta University · USBanyan Biomarkers (United States) · USInstitute of Pharmacology · CZQueen's University · CAUniversity of Colorado Anschutz Medical Campus · US

Funding

eNOS-actin Interaction and Oxygen in Lung EndotheliumR01HL088261 · NHLBI · UNIVERSITY OF FLORIDA · PI SU, YUNCHAO · 2008 to 2012
$1.8M
CIHR MOP-81189NHLBI NIH HHS R01 HL088261NHLBI NIH HHS R01HL088261
6 · The paper itself

Abstract

Pulmonary hypertension is a severe and progressive disease, a key feature of which is pulmonary vascular remodeling. Several growth factors, including EGF, PDGF, and TGF-β1, are involved in pulmonary vascular remodeling during pulmonary hypertension. However, increased knowledge of the downstream signaling cascades is needed if effective clinical interventions are to be developed. In this context, calpain provides an interesting candidate therapeutic target, since it is activated by EGF and PDGF and has been reported to activate TGF-β1. Thus, in this study, we examined the role of calpain in pulmonary vascular remodeling in two rodent models of pulmonary hypertension. These data showed that attenuated calpain activity in calpain-knockout mice or rats treated with a calpain inhibitor resulted in prevention of increased right ventricular systolic pressure, right ventricular hypertrophy, as well as collagen deposition and thickening of pulmonary arterioles in models of hypoxia- and monocrotaline-induced pulmonary hypertension. Additionally, inhibition of calpain in vitro blocked intracellular activation of TGF-β1, which led to attenuated Smad2/3 phosphorylation and collagen synthesis. Finally, smooth muscle cells of pulmonary arterioles from patients with pulmonary arterial hypertension showed higher levels of calpain activation and intracellular active TGF-β. Our data provide evidence that calpain mediates EGF- and PDGF-induced collagen synthesis and proliferation of pulmonary artery smooth muscle cells via an intracrine TGF-β1 pathway in pulmonary hypertension.

Indexed as

AnimalsArteriolesBecaplerminCalpainCell ProliferationCollagen Type ICysteine Proteinase InhibitorsDipeptidesDisease Models, AnimalEpidermal Growth FactorFamilial Primary Pulmonary HypertensionGene Knockout TechniquesHumansHypertension, PulmonaryLungMaleBecaplerminCalpaincalpain inhibitor IIICapns1 protein, mouseCollagen Type ICysteine Proteinase InhibitorsDipeptidesEpidermal Growth FactorPlatelet-Derived Growth FactorProto-Oncogene Proteins c-sisRNA, Small InterferingSmad ProteinsTransforming Growth Factor beta1

Identifiers

PMID22005303
PMCPMC3204840
OpenAlexW2050988768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.